Glenmark Pharma Goa Facility Receives 6 Observations from US FDA

Glenmark Pharmaceuticals Ltd announced that its manufacturing facility in Goa, India, underwent a GMP inspection by the U.S. FDA from June 22 to June 30, 2026. The inspection resulted in the issuance of a Form 483 with six observations. Notably, there were no data integrity issues reported, and all observations are procedural and not repeat findings. The company anticipates no impact on the supply of its commercial products and plans to address the observations collaboratively with the U.S. FDA within the stipulated timeline. Further updates will be provided to the stock exchanges as necessary.